Loading treatment…
Compounded — not FDA-approvedPrescription only
Compounded Tesamorelin
Compounded — daily injection
A compounded daily injection of a growth-hormone-releasing hormone analogue. The brand-name product is approved only for HIV-associated abdominal fat; any use here is a provider's documented, off-label judgment.
Compounded tesamorelin is prepared for you by a licensed 503A compounding pharmacy and is not FDA-approved. It uses the active ingredient of Egrifta but is not that product, and the FDA has not reviewed it for safety, effectiveness or quality. A provider may prescribe it only where they document a clinical reason it is right for you specifically. Egrifta's approval covers only excess abdominal fat in adults with HIV-associated lipodystrophy; any other use is off-label, which your provider will explain.
From$229/mo$32 consultation included, not refunded · medication and shipping if prescribed
Choose your plan
4-week supply
Price
$229for a 4-week supply, if prescribed
Includes your $32 provider consultation (non-refundable). If your provider decides treatment isn’t appropriate, the medication portion is refunded automatically.
- Your provider confirms the dose. If they start you on a lower step, we refund the difference; if they choose a higher one within the same plan, the price you paid stands.
Adding to cart books a provider visit. You pay the shown total; the provider decides; the medication portion comes back automatically if they say no.
Questions
Will I definitely be prescribed this?
No — a consultation does not guarantee a prescription. Egrifta is commercially available, so a compounding pharmacy may prepare tesamorelin for you only where your prescriber documents a specific clinical reason the commercial product is not right for you, and the use itself is off-label outside HIV-associated lipodystrophy. Many providers will reasonably decline. If yours does, we'll tell you why and the medication portion of your payment is refunded; the consultation fee is not.
Is this a weight-loss injection?
No. The approved product's label says plainly that it is weight-neutral and not indicated for weight-loss management; the effect measured in its trials was on visceral fat in a specific HIV-related condition. If weight is the goal, the weight-loss section is the honest place to start.
How is it different from sermorelin?
Both signal the pituitary to release your own growth hormone. Sermorelin is the first 29 amino acids of GHRH; tesamorelin is the full-length hormone stabilised against breakdown, and it is the one with a still-marketed approved product behind it — which is also why prescribing a compounded copy needs a documented, patient-specific reason. We don't rank them; your provider chooses with your history in front of them.
How it works
Tesamorelin is a synthetic analogue of the full growth-hormone-releasing hormone (GHRH), with a chemical group added at one end so it resists the enzymes that break the natural hormone down within minutes. It binds GHRH receptors on the pituitary, which releases your own growth hormone in pulses; the liver responds by making IGF-1. Your body's own brakes — somatostatin and the feedback from IGF-1 — stay in place, which is the difference from injecting growth hormone directly. In the trials that led to approval, in adults with HIV whose treatment had shifted fat into the abdomen, the measured effect was on visceral fat specifically: body weight did not change, and the label says so. Sermorelin, on the same account, is a shorter fragment of the same hormone; neither is ranked above the other here, and which — if either — fits you is your provider's call. Outside HIV-associated lipodystrophy, the outcome data is thin, and the raised IGF-1 is why cancer history is a hard stop.
The full mechanismWhat the trials found
Published results, with what each was measured against.
These results come from trials of the FDA-approved product named in each citation. The compounded preparation on this page is not that product, was not studied in these trials, and has not been reviewed by the FDA for safety, effectiveness or quality.
20% reduction in visceral adipose tissue by CT scan at 26 weeks
vs a 2% increase on placebo
Study 1 of the approved product, in adults with HIV-associated lipodystrophy and excess abdominal fat; body weight did not change. No comparable trial exists in people without that condition, and the compounded product was not the one studied.
Egrifta WR prescribing information, section 14, DailyMed, revised 03/2025; Falutz et al., New England Journal of Medicine, 2007
Trial averages describe a study population, not a prediction for you. Your provider will be direct about what is realistic given your history — and results depend on continuing treatment.
A provider may consider it if
- You and your provider have discussed the peptides lane and why this molecule rather than sermorelin, or neither
- You can commit to a daily injection and to blood-sugar and IGF-1 checks as your provider directs
- You understand this is off-label outside its approved use, and that the evidence in people without HIV lipodystrophy is thin
It won’t be prescribed if
- Active cancer, or a history of it, without your oncologist involved — the approved product is contraindicated in active malignancy because it raises IGF-1, a growth factor, and this is a hard stop
- Pregnancy, trying to become pregnant, or breastfeeding — the approved label contraindicates it in pregnancy
- Any disruption of the hypothalamic-pituitary axis: pituitary surgery or tumour, hypopituitarism, head irradiation or serious head trauma
- Uncontrolled diabetes or prediabetes without a plan to monitor it — the approved label warns of glucose intolerance and new diabetes
- Anyone expecting weight loss — the approved label states it is weight-neutral, and we will not imply otherwise
- Acute critical illness, such as recovery from major surgery or intensive care
These are the same checks your provider runs in the visit. If one applies, they will tell you plainly — and the medication portion of what you paid comes back automatically.
What to expect
Weeks 1–4
Injection-site redness and itching, joint and muscle aches, and some fluid retention in the hands or ankles are the common early experiences on the approved product. Your provider may check fasting glucose before you start.
Months 2–3
Where your provider reviews IGF-1 and blood sugar and decides whether to continue. In the approval trials the visceral-fat effect was measured at six months; anything you notice sooner is not the mechanism.
Ongoing
Reviewed at check-ins like any long-term prescription. On the approved product the effect reversed after stopping, so continuing is a decision to revisit, not a default.
Safety
Side effects, before you decide
Joint pain, injection-site redness and itching, pain in the arms or legs, swelling in the hands or feet and muscle aches were the common ones on the approved product. It raises IGF-1, a growth factor, which is why active cancer is a hard stop and a treated cancer needs your oncologist's view. It can raise blood sugar and unmask diabetes. Hypersensitivity reactions, including rash and hives, are reported. Long-term cardiovascular safety has not been established, and there is no safety data from long-term use in people without HIV-associated lipodystrophy.
- Egrifta WR (tesamorelin for injection) prescribing information, DailyMed, revised 03/2025 — indication, contraindications, warnings and section 14 clinical studies
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007;357:2359–2370
Complete safety information is provided during your visit and with every prescription. This page is a summary, not a substitute for your provider's advice.
Also for longevity
Compounded NAD+From$229/mo$32 consultation included, not refunded · medication and shipping if prescribed
Compounded SermorelinFrom$209/mo$32 consultation included, not refunded · medication and shipping if prescribed
Compounded Low-Dose NaltrexoneFrom$169/mo$32 consultation included, not refunded · medication and shipping if prescribed
Compounded GlutathioneFrom$209/mo$32 consultation included, not refunded · medication and shipping if prescribed
Compounded Methylene BlueFrom$129/mo$32 consultation included, not refunded · medication and shipping if prescribed
Compounded B12 / Glutathione / NAD+ / Sermorelin BundleFrom$379/mo$32 consultation included, not refunded · medication and shipping if prescribed
See whether compounded tesamorelin is right for you.
A licensed provider reviews your visit and decides. You receive medication only if prescribed, and that portion of your payment is refunded automatically if they say no.